Status:

UNKNOWN

Brain/Neural Hand Exoskeleton Control for Restoration of Bimanual Tasks

Lead Sponsor:

University Hospital Tuebingen

Collaborating Sponsors:

Charite University, Berlin, Germany

Reutlingen University

Conditions:

Spinal Cord Injury

Stroke

Eligibility:

All Genders

18-68 years

Phase:

NA

Brief Summary

This study investigates whether spinal cord injury and stroke survivors (n=10) are able to operate a brain/neural hand exoskeleton (B/NHE) based on electroencephalography (EEG) and electrooculography ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (Stroke):
  • single ischemic or hemorrhagic insult with subcortical lesion (medullary canal, internal capsula, pedunculi cerebri)
  • interval since stroke at least 6 months
  • substantial motor deficit with:
  • Medical Research Council (MRC) -score of less than 2 out of 6 possible points (0=no activity; 1=visible contraction without motor effect; 2=movements with elimination of gravity; 3=movements against gravity; 4=movements against weak resistance; 5=normal force)
  • Fugl-Meyer Test (upper extremity) of less than 31 points, "no to little mobility"
  • Inclusion Criteria (Spinal Cord Injury):
  • cervical spinal cord injury, height C5-C6
  • interval after spinal cord injury at least 6 months
  • substantial motor deficit with American Spinal Cord Association (ASIA) -Classification B or C (A=no muscle function/sensitivity below the spinal cord injury; B=no muscle function, limited sensitivity present; C=low non-relevant muscle function, sensitivity present; D=functionally relevant muscle functions present; E=fully preserved or restored functions)
  • Exclusion Criteria (Stroke and Spinal Cord Injury):
  • Alcohol or drug problem (regular consumption of more than 2 alcoholic beverages per day, or taking illegal drugs)
  • currently undergoing neurological or psychiatric treatment based on a secondary diagnosis
  • Severe and uncontrollable medical problems:
  • Non-adjusted malignant high blood pressure, World Health Organization (WHO) Hypertension Grade II
  • non-adjustable diabetes mellitus, HbA1c \> 58 mmol/mol
  • renal failure, from KDIGO glomerular filtration rate (GFR) category G3b (moderate to severe impairment)
  • Liver failure, Child-Pugh stages B and C
  • Heart failure New York Heart Association (NYHA) grade III-IV
  • malignant tumor disease
  • severe arrhythmia in need of treatment
  • severe oedemas
  • severe arthritis
  • serious cognitive impairment (minimum status below 23 points)
  • Severe spasticity (Ashworth grade ≥ 4)
  • Pregnancy
  • Bilateral motor deficit (in stroke patients)

Exclusion

    Key Trial Info

    Start Date :

    June 1 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 1 2020

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT04440709

    Start Date

    June 1 2020

    End Date

    October 1 2020

    Last Update

    June 22 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    University Hospital Tuebingen

    Tübingen, Baden-Wurttemberg, Germany, 72076

    2

    Charité - University Medicine Berlin

    Berlin, Germany, 10117